HeartSciences Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2026 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 HEARTSCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of March 16, 2026, the registrant had 3,184,700shares of Common Stock outstanding. HEARTSCIENCES INC. NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Theseforward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by terminology such as“may,” “will,” “should,” “expects,” “aims,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” orthe negative of these terms or other comparable terminology. Readers are cautioned that these forward-looking statements are based on ourcurrent beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, includingthose identified below, under Part II, Item 1A “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and those risks identifiedunder Part I, Item 1A of our Annual Report on Form 10-K for the year ended April 30, 2025 filed with the U.S. Securities and ExchangeCommission (the “SEC”) on July 24, 2025 (the “2025 Annual Report on Form 10-K”). Therefore, actual results may differ materially andadversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update anyforward-looking statements for any reason. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies,statements that contain projections of results of operations or of financial condition, expected capital needs and expenses, statements relatingto the research, development, completion and use of our device, and all statements (other than statements of historical facts) that addressactivities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based theseforward-looking statements on assumptions and assessments made by our management in light of their experience and their perception ofhistorical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated inthese forward-looking statements include, among other things: ●our expectation regarding the sufficiency of our existing cash and cash equivalents to fund our current operations;●our ability to receive regulatory clearances for the MyoVistawavECG or the MyoVista Insights platform (“MyoVista Insights”),and associated AI-ECG algorithms from the U.S. Food and Drug Administration (the “FDA”), state regulators, if any, or othersimilar foreign regulatory agencies, including approval to conduct clinical trials, the timing and scope of those